Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,132.40
(
0.00%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.45
(
-1.20%
)
Bitcoin
73,925.75
(
-0.02%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 144897

Monday, 07/02/2012 1:42:08 PM

Monday, July 02, 2012 1:42:08 PM

Post# of 257253

Too bad MNTA is now wasting their money in the overcrowded oncology space. :)

LOL—apparently you plan to use this soundbite as often as you can :- ) In case some reader didn’t realize you were being facetious, let me note that M402 represents less than 2% of MNTA’s underlying value according to any reasonable analysis I can envision.

In other words, MNTA is not one of the myriad clones of small biotech companies pursuing near-hopeless odds with a cadre of cancer drug candidates.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now